Cellestia

Cellestia is actively involved in the clinical development of first-in-class targeted therapies with untapped modes of action to address unmet medical needs for patients with oncology and immunological diseases. The company is developing CB-103, a novel, first-in-class oral pan-NOTCH inhibitor with a unique mechanism of action for the treatment of NOTCH-dependent leukemia, lymphoma, and solid tumors.